摘要
Recent studies have shown that reprogramming of cholesterol metabolism occurs in both tumor cells and immune cells.Therapeutic strategies to inhibit the cholesterol synthesis pathway also interfere with normal metabolic homeostasis and actions of immune cells.Thus,it is urgent to develop anti-tumor drugs that maintain a balance between inhibiting tumor cells and maintaining immune cell activity for anti-tumor metabolic immunotherapy.We will focus this review on the interaction between cholesterol and immune cells,effects of cholesterol and its metabolites on the pathogenesis and development of tumors,and strategies for developing antitumor therapies based on cholesterol metabolism.It has been shown that leelamine and modulators targeting cholesterol esters,27-hydroxycholesterol,and Dendrogenin A are potential candidates for anti-tumor metabolic therapy.Particularly,the ACAT inhibitor avasimibe,an established target for atherosclerosis,has attracted the attention of clinical researches because of its unique influence on both inhibiting tumor cells and enhancing immune cell function,which are expected to provide new research directions for cancer treatment.
